FDA
-
-
-
-
-
-
-
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
-
-
-
-
-
-
-
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
-
-
-
-
-
-
-
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
-
-
-
-
-
-
-
NervGen appoints Adam Rogers as permanent CEO
-
-
-
-
-
-
-
NervGen Pharma To Webcast At VirtualInvestorConferences.com July 11th
-
-
331,842 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

